 WATERTOWN, Mass.--BUSINESS WIRE--SQZ Biotechnologies NYSE: SQZ, a cell therapy company developing novel potential treatments for multiple therapeutic areas, announced today that the Immune Tolerance group leader, Shinu John, PhD, will present new preclinical data from the companys Tolerizing Antigen Carriers SQZTM TACs platform in an invited talk at the Antigen-Specific Immune Tolerance ASIT Digital Summit taking place January 26, 2021 through January 28, 2021. SQZ TACs are a red blood 